| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Methylnaltrexone | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | | Methylnaltrexone | hsa00500 | Starch and sucrose metabolism | 9.22E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Methylnaltrexone | hsa00730 | Thiamine metabolism | 4.66E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Methylnaltrexone | hsa00770 | Pantothenate and CoA biosynthesis | 7.90E-03 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | | Methylnaltrexone | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.58E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | | Methylnaltrexone | hsa01524 | Platinum drug resistance | 1.13E-02 | 5 | P10415, Q13489, P78417, P23025, P43246 | BCL2, BIRC3, GSTO1, XPA, MSH2 | More | | | Methylnaltrexone | hsa03008 | Ribosome biogenesis in eukaryotes | 2.60E-03 | 5 | Q9NYH9, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, RPP38, GNL3, NVL, NXF2; NXF2B | More | | | Methylnaltrexone | hsa03013 | RNA transport | 2.29E-04 | 13 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, TACC3, FXR1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P21462 | FPR1 | fMet-Leu-Phe receptor | O14980 | XPO1 | Exportin-1 | -0.742 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | -0.874 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | 0.924 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q09161 | NCBP1 | Nuclear cap-binding protein subunit 1 | -0.78 | | P21462 | FPR1 | fMet-Leu-Phe receptor | O14893 | GEMIN2 | Gem-associated protein 2 | -0.87 | | P51684 | CCR6 | C-C chemokine receptor type 6 | O14893 | GEMIN2 | Gem-associated protein 2 | 0.771 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P61326 | MAGOH | Protein mago nashi homolog | -0.835 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P61326 | MAGOH | Protein mago nashi homolog | 0.704 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q7Z3B4 | NUP54 | Nucleoporin p54 | -0.903 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q7Z3B4 | NUP54 | Nucleoporin p54 | 0.811 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P35658 | NUP214 | Nuclear pore complex protein Nup214 | 0.971 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | -0.89 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | 0.701 | | P21462 | FPR1 | fMet-Leu-Phe receptor | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | -0.953 | | P51684 | CCR6 | C-C chemokine receptor type 6 | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | 0.711 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P78345 | RPP38 | Ribonuclease P protein subunit p38 | 0.861 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14240 | EIF4A2 | Eukaryotic initiation factor 4A-II | -0.721 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | 0.904 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | -0.732 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P51114 | FXR1 | Fragile X mental retardation syndrome-related protein 1 | -0.713 | | P21462 | FPR1 | fMet-Leu-Phe receptor | O14980 | XPO1 | Exportin-1 | -0.742 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | -0.874 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | 0.924 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q09161 | NCBP1 | Nuclear cap-binding protein subunit 1 | -0.78 | | P21462 | FPR1 | fMet-Leu-Phe receptor | O14893 | GEMIN2 | Gem-associated protein 2 | -0.87 | | P51684 | CCR6 | C-C chemokine receptor type 6 | O14893 | GEMIN2 | Gem-associated protein 2 | 0.771 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P61326 | MAGOH | Protein mago nashi homolog | -0.835 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P61326 | MAGOH | Protein mago nashi homolog | 0.704 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q7Z3B4 | NUP54 | Nucleoporin p54 | -0.903 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q7Z3B4 | NUP54 | Nucleoporin p54 | 0.811 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P35658 | NUP214 | Nuclear pore complex protein Nup214 | 0.971 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | -0.89 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | 0.701 | | P21462 | FPR1 | fMet-Leu-Phe receptor | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | -0.953 | | P51684 | CCR6 | C-C chemokine receptor type 6 | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | 0.711 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P78345 | RPP38 | Ribonuclease P protein subunit p38 | 0.861 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14240 | EIF4A2 | Eukaryotic initiation factor 4A-II | -0.721 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | 0.904 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | -0.732 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P51114 | FXR1 | Fragile X mental retardation syndrome-related protein 1 | -0.713 |
| | Methylnaltrexone | hsa03040 | Spliceosome | 5.79E-03 | 7 | Q14562, O43143, O60508, Q99633, Q13595, Q01130, Q9UMS4 | DHX8, DHX15, CDC40, PRPF18, TRA2A, SFRS2, PRPF19 | More | | | Methylnaltrexone | hsa04015 | Rap1 signaling pathway | 1.58E-02 | 6 | P20827, P49767, P63261, P25116, P0DP23, P17252 | EFNA1, VEGFC, ACTG1, F2R, CALM1, PRKCA | More | | | Methylnaltrexone | hsa04020 | Calcium signaling pathway | 1.16E-03 | 7 | Q16566, P17252, O15399, P25116, P0DP23, P23634, P49767 | CAMK4, PRKCA, GRIN2D, F2R, CALM1, ATP2B4, VEGFC | More | | | Methylnaltrexone | hsa04024 | cAMP signaling pathway | 2.84E-02 | 5 | P0DP23, P23634, Q16566, O15399, P25116 | CALM1, ATP2B4, CAMK4, GRIN2D, F2R | More | | | Methylnaltrexone | hsa04062 | Chemokine signaling pathway | 3.93E-03 | 10 | P25024, P25025, P47992, Q9UBD3, P07948, P63218, P50151, P49407, Q08881, P49841 | CXCR1, CXCR2, XCL1, XCL2, LYN, GNG5, GNG10, ARRB1, ITK, GSK3B | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 1 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P47992 | XCL1 | Lymphotactin | -0.706 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.706 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.707 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49407 | ARRB1 | Beta-arrestin-1 | -0.721 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 1 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P47992 | XCL1 | Lymphotactin | -0.706 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.706 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P09769 | FGR | Tyrosine-protein kinase Fgr | 0.796 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.971 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.707 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43250 | GRK6 | G protein-coupled receptor kinase 6 | 0.818 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49407 | ARRB1 | Beta-arrestin-1 | -0.721 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | 0.706 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q8WYR1 | PIK3R5 | Phosphoinositide 3-kinase regulatory subunit 5 | 0.752 |
| | Methylnaltrexone | hsa04064 | NF-kappa B signaling pathway | 4.92E-02 | 6 | P10415, P51617, Q13546, Q9UDY8, Q13077, P24522 | BCL2, IRAK1, RIPK1, MALT1, TRAF1, GADD45A | More | | | Methylnaltrexone | hsa04070 | Phosphatidylinositol signaling system | 4.07E-02 | 4 | P0DP23, Q14643, O14732, P17252 | CALM1, ITPR1, IMPA2, PRKCA | More | | | Methylnaltrexone | hsa04071 | Sphingolipid signaling pathway | 1.90E-03 | 8 | P17252, Q9H228, P01375, Q13362, Q16537, Q9BX95, P04637, P10415 | PRKCA, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2 | More | | | Methylnaltrexone | hsa04145 | Phagosome | 1.86E-02 | 5 | P63261, Q15080, Q13509, P68371, P27824 | ACTG1, NCF4, TUBB3, TUBB2C, CANX | More | | | Methylnaltrexone | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.44E-02 | 5 | Q16537, P0DP23, P17252, P10415, P20020 | PPP2R5E, CALM1, PRKCA, BCL2, ATP2B1 | More | | | Methylnaltrexone | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | | Methylnaltrexone | hsa04390 | Hippo signaling pathway | 1.47E-02 | 5 | P63261, Q13485, Q9UJU2, O43623, Q13489 | ACTG1, SMAD4, LEF1, SNAI2, BIRC3 | More | | | Methylnaltrexone | hsa04510 | Focal adhesion | 3.21E-02 | 6 | Q15942, P17252, Q13489, P10415, P49767, P63261 | ZYX, PRKCA, BIRC3, BCL2, VEGFC, ACTG1 | More | | | Methylnaltrexone | hsa04520 | Adherens junction | 3.36E-02 | 4 | Q13485, Q9UJU2, O43623, P63261 | SMAD4, LEF1, SNAI2, ACTG1 | More | | | Methylnaltrexone | hsa04540 | Gap junction | 4.76E-02 | 3 | P17252, Q13509, P68371 | PRKCA, TUBB3, TUBB2C | More | | | Methylnaltrexone | hsa04612 | Antigen processing and presentation | 1.51E-02 | 7 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A | More | | | Methylnaltrexone | hsa04613 | Neutrophil extracellular trap formation | 1.68E-02 | 9 | P17252, O60603, P08246, Q92769, Q6FI13, P33778, P14598, Q15080, P21462 | PRKCA, TLR2, ELA2, HDAC2, H2AC18; H2AC19, H2BC3, NCF1, NCF4, FPR1 | More | | | Methylnaltrexone | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | | Methylnaltrexone | hsa04650 | Natural killer cell mediated cytotoxicity | 7.01E-05 | 10 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| | Methylnaltrexone | hsa04660 | T cell receptor signaling pathway | 1.49E-03 | 10 | P01375, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| | Methylnaltrexone | hsa04666 | Fc gamma R-mediated phagocytosis | 2.22E-02 | 4 | P49006, P06396, P14598, P17252 | MARCKSL1, GSN, NCF1, PRKCA | More | | | Methylnaltrexone | hsa04720 | Long-term potentiation | 3.70E-04 | 5 | P17252, Q16566, P0DP23, O15399, Q14643 | PRKCA, CAMK4, CALM1, GRIN2D, ITPR1 | More | | | Methylnaltrexone | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | | Methylnaltrexone | hsa04912 | GnRH signaling pathway | 4.42E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | | Methylnaltrexone | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | | Methylnaltrexone | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | | Methylnaltrexone | hsa04925 | Aldosterone synthesis and secretion | 2.90E-04 | 6 | Q14643, P0DP23, P17252, Q16566, P20020, P23634 | ITPR1, CALM1, PRKCA, CAMK4, ATP2B1, ATP2B4 | More | | | Methylnaltrexone | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.36E-02 | 4 | Q13485, P10415, P49767, P17252 | SMAD4, BCL2, VEGFC, PRKCA | More | | | Methylnaltrexone | hsa04966 | Collecting duct acid secretion | 3.15E-02 | 2 | P02730, Q9Y666 | SLC4A1, SLC12A7 | More | | | Methylnaltrexone | hsa04970 | Salivary secretion | 8.71E-04 | 5 | Q14643, P20020, P23634, P17252, P0DP23 | ITPR1, ATP2B1, ATP2B4, PRKCA, CALM1 | More | | | Methylnaltrexone | hsa04971 | Gastric acid secretion | 4.76E-02 | 3 | P17252, P63261, P0DP23 | PRKCA, ACTG1, CALM1 | More | | | Methylnaltrexone | hsa04972 | Pancreatic secretion | 1.00E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | | Methylnaltrexone | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | | Methylnaltrexone | hsa05014 | Amyotrophic lateral sclerosis | 4.31E-02 | 7 | O15399, P10415, Q13509, P68371, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, TUBB3, TUBB2C, GLE1, ACTG1, NXF2; NXF2B | More | | | Methylnaltrexone | hsa05031 | Amphetamine addiction | 1.49E-02 | 4 | O15399, P0DP23, Q16566, P17252 | GRIN2D, CALM1, CAMK4, PRKCA | More | | | Methylnaltrexone | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.11E-02 | 4 | Q16539, P25024, P25025, P07948 | MAPK14, CXCR1, CXCR2, LYN | More | | | Methylnaltrexone | hsa05132 | Salmonella infection | 2.12E-04 | 13 | P51617, Q9UJU2, P63261, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371 | IRAK1, LEF1, ACTG1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C | More | | | Methylnaltrexone | hsa05133 | Pertussis | 2.52E-02 | 3 | P0DP23, P23528, P09871 | CALM1, CFL1, C1S | More | | | Methylnaltrexone | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | | Methylnaltrexone | hsa05140 | Leishmaniasis | 1.56E-02 | 5 | P14598, O60603, P49006, P51617, Q15080 | NCF1, TLR2, MARCKSL1, IRAK1, NCF4 | More | | | Methylnaltrexone | hsa05144 | Malaria | 1.64E-03 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | | Methylnaltrexone | hsa05163 | Human cytomegalovirus infection | 1.72E-02 | 8 | P01375, P63218, P50151, P49841, P14778, P25025, Q16539, O00463 | TNF, GNG5, GNG10, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | | | Methylnaltrexone | hsa05168 | Herpes simplex virus 1 infection | 1.94E-02 | 9 | Q9UKJ0, P01568, Q9GZY0, Q01130, Q13489, Q13398, Q03923, Q9UDV6, P10415 | PILRB, IFNA21, NXF2; NXF2B, SFRS2, BIRC3, ZNF211, ZNF85, ZNF212, BCL2 | More | | | Methylnaltrexone | hsa05169 | Epstein-Barr virus infection | 2.54E-02 | 8 | Q92769, P04637, Q13546, P10415, P24522, O60603, P51617, P09693 | HDAC2, TP53, RIPK1, BCL2, GADD45A, TLR2, IRAK1, CD3G | More | | | Methylnaltrexone | hsa05170 | Human immunodeficiency virus 1 infection | 6.54E-03 | 9 | P0DP23, P17252, Q13546, Q14643, P51617, O60603, P09693, P10415, Q9Y6Q5 | CALM1, PRKCA, RIPK1, ITPR1, IRAK1, TLR2, CD3G, BCL2, AP1M2 | More | | | Methylnaltrexone | hsa05200 | Pathways in cancer | 1.51E-02 | 12 | Q9UJU2, P17252, P43246, Q13485, P14923, P10415, Q13489, P49767, P25116, P78417, P0DP23, P01568 | LEF1, PRKCA, MSH2, SMAD4, JUP, BCL2, BIRC3, VEGFC, F2R, GSTO1, CALM1, IFNA21 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P46091 | GPR1 | Chemerin-like receptor 2 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.736 | | P46091 | GPR1 | Chemerin-like receptor 2 | P17252 | PRKCA | Protein kinase C alpha type | 0.741 | | P46091 | GPR1 | Chemerin-like receptor 2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.838 | | P46091 | GPR1 | Chemerin-like receptor 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.809 | | P46091 | GPR1 | Chemerin-like receptor 2 | P14923 | JUP | Junction plakoglobin | 0.883 | | P46091 | GPR1 | Chemerin-like receptor 2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.808 | | P46091 | GPR1 | Chemerin-like receptor 2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.759 | | P46091 | GPR1 | Chemerin-like receptor 2 | P49767 | VEGFC | Vascular endothelial growth factor C | 0.718 | | P46091 | GPR1 | Chemerin-like receptor 2 | P25116 | F2R | Proteinase-activated receptor 1 | 0.76 | | P46091 | GPR1 | Chemerin-like receptor 2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | 0.738 | | P46091 | GPR1 | Chemerin-like receptor 2 | P0DP23 | CALM1 | Calmodulin-1 | -0.846 | | P46091 | GPR1 | Chemerin-like receptor 2 | P01568 | IFNA21 | Interferon alpha-21 | 0.724 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | | P46091 | GPR1 | Chemerin-like receptor 2 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.736 | | P46091 | GPR1 | Chemerin-like receptor 2 | P17252 | PRKCA | Protein kinase C alpha type | 0.741 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | | P46091 | GPR1 | Chemerin-like receptor 2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.838 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | | P46091 | GPR1 | Chemerin-like receptor 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.809 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | | P46091 | GPR1 | Chemerin-like receptor 2 | P14923 | JUP | Junction plakoglobin | 0.883 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | | P46091 | GPR1 | Chemerin-like receptor 2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.808 | | P46091 | GPR1 | Chemerin-like receptor 2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.759 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | | P46091 | GPR1 | Chemerin-like receptor 2 | P49767 | VEGFC | Vascular endothelial growth factor C | 0.718 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | | P46091 | GPR1 | Chemerin-like receptor 2 | P25116 | F2R | Proteinase-activated receptor 1 | 0.76 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | | P46091 | GPR1 | Chemerin-like receptor 2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | 0.738 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | | P46091 | GPR1 | Chemerin-like receptor 2 | P0DP23 | CALM1 | Calmodulin-1 | -0.846 | | P46091 | GPR1 | Chemerin-like receptor 2 | P01568 | IFNA21 | Interferon alpha-21 | 0.724 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 |
| | Methylnaltrexone | hsa05212 | Pancreatic cancer | 3.40E-02 | 1 | P37173 | TGFBR2 | More | | | Methylnaltrexone | hsa05214 | Glioma | 8.71E-04 | 5 | P0DP23, Q16566, P17252, P04637, P24522 | CALM1, CAMK4, PRKCA, TP53, GADD45A | More | | | Methylnaltrexone | hsa05216 | Thyroid cancer | 1.85E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | | Methylnaltrexone | hsa05217 | Basal cell carcinoma | 4.42E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | | Methylnaltrexone | hsa05418 | Fluid shear stress and atherosclerosis | 2.49E-03 | 11 | Q16539, P78417, P10599, P14780, P01375, P63261, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, GSTO1, TXN, MMP9, TNF, ACTG1, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | | | Naltrexone | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | | Naltrexone | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | | Naltrexone | hsa00500 | Starch and sucrose metabolism | 5.45E-05 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Naltrexone | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | | Naltrexone | hsa00730 | Thiamine metabolism | 7.19E-04 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Naltrexone | hsa00770 | Pantothenate and CoA biosynthesis | 7.90E-03 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | | Naltrexone | hsa00970 | Aminoacyl-tRNA biosynthesis | 9.22E-06 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | | Naltrexone | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | | Naltrexone | hsa01522 | Endocrine resistance | 4.51E-02 | 2 | P04637, P42773 | TP53, CDKN2C | More | | | Naltrexone | hsa01524 | Platinum drug resistance | 1.13E-02 | 5 | P10415, Q13489, P78417, P23025, P43246 | BCL2, BIRC3, GSTO1, XPA, MSH2 | More | | | Naltrexone | hsa03008 | Ribosome biogenesis in eukaryotes | 2.60E-03 | 5 | Q9NYH9, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, RPP38, GNL3, NVL, NXF2; NXF2B | More | | | Naltrexone | hsa03013 | RNA transport | 2.29E-04 | 13 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, TACC3, FXR1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P21462 | FPR1 | fMet-Leu-Phe receptor | O14980 | XPO1 | Exportin-1 | -0.742 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | -0.874 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | 0.924 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q09161 | NCBP1 | Nuclear cap-binding protein subunit 1 | -0.78 | | P21462 | FPR1 | fMet-Leu-Phe receptor | O14893 | GEMIN2 | Gem-associated protein 2 | -0.87 | | P51684 | CCR6 | C-C chemokine receptor type 6 | O14893 | GEMIN2 | Gem-associated protein 2 | 0.771 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P61326 | MAGOH | Protein mago nashi homolog | -0.835 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P61326 | MAGOH | Protein mago nashi homolog | 0.704 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q7Z3B4 | NUP54 | Nucleoporin p54 | -0.903 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q7Z3B4 | NUP54 | Nucleoporin p54 | 0.811 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P35658 | NUP214 | Nuclear pore complex protein Nup214 | 0.971 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | -0.89 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | 0.701 | | P21462 | FPR1 | fMet-Leu-Phe receptor | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | -0.953 | | P51684 | CCR6 | C-C chemokine receptor type 6 | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | 0.711 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P78345 | RPP38 | Ribonuclease P protein subunit p38 | 0.861 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14240 | EIF4A2 | Eukaryotic initiation factor 4A-II | -0.721 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | 0.904 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | -0.732 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P51114 | FXR1 | Fragile X mental retardation syndrome-related protein 1 | -0.713 | | P21462 | FPR1 | fMet-Leu-Phe receptor | O14980 | XPO1 | Exportin-1 | -0.742 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | -0.874 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | 0.924 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q09161 | NCBP1 | Nuclear cap-binding protein subunit 1 | -0.78 | | P21462 | FPR1 | fMet-Leu-Phe receptor | O14893 | GEMIN2 | Gem-associated protein 2 | -0.87 | | P51684 | CCR6 | C-C chemokine receptor type 6 | O14893 | GEMIN2 | Gem-associated protein 2 | 0.771 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P61326 | MAGOH | Protein mago nashi homolog | -0.835 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P61326 | MAGOH | Protein mago nashi homolog | 0.704 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q7Z3B4 | NUP54 | Nucleoporin p54 | -0.903 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q7Z3B4 | NUP54 | Nucleoporin p54 | 0.811 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P35658 | NUP214 | Nuclear pore complex protein Nup214 | 0.971 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | -0.89 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | 0.701 | | P21462 | FPR1 | fMet-Leu-Phe receptor | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | -0.953 | | P51684 | CCR6 | C-C chemokine receptor type 6 | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | 0.711 | | P51684 | CCR6 | C-C chemokine receptor type 6 | P78345 | RPP38 | Ribonuclease P protein subunit p38 | 0.861 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14240 | EIF4A2 | Eukaryotic initiation factor 4A-II | -0.721 | | P21462 | FPR1 | fMet-Leu-Phe receptor | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | 0.904 | | P51684 | CCR6 | C-C chemokine receptor type 6 | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | -0.732 | | P21462 | FPR1 | fMet-Leu-Phe receptor | P51114 | FXR1 | Fragile X mental retardation syndrome-related protein 1 | -0.713 |
| | Naltrexone | hsa03040 | Spliceosome | 3.10E-07 | 16 | Q14562, O43143, O60508, Q99633, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, Q9UMS4, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, PRPF18, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, PRPF19, HSPA8, WBP11, PPIH, ASCC3L1 | More | | | Naltrexone | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | | Naltrexone | hsa04015 | Rap1 signaling pathway | 9.35E-04 | 12 | P20827, P49767, P63261, Q96FS4, P11215, P25116, Q13009, Q7LDG7, P42338, P0DP23, P17252, P19174 | EFNA1, VEGFC, ACTG1, SIPA1, ITGAM, F2R, TIAM1, RASGRP2, PIK3CB, CALM1, PRKCA, PLCG1 | More | | | Naltrexone | hsa04020 | Calcium signaling pathway | 1.16E-03 | 7 | Q16566, P17252, O15399, P25116, P0DP23, P23634, P49767 | CAMK4, PRKCA, GRIN2D, F2R, CALM1, ATP2B4, VEGFC | More | | | Naltrexone | hsa04024 | cAMP signaling pathway | 2.84E-02 | 5 | P0DP23, P23634, Q16566, O15399, P25116 | CALM1, ATP2B4, CAMK4, GRIN2D, F2R | More | | | Naltrexone | hsa04062 | Chemokine signaling pathway | 1.43E-04 | 17 | P25024, P25025, P47992, Q9UBD3, P09769, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q08881, Q7LDG7, Q13009, P49841, Q8WYR1 | CXCR1, CXCR2, XCL1, XCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, ITK, RASGRP2, TIAM1, GSK3B, PIK3R5 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 1 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P47992 | XCL1 | Lymphotactin | -0.706 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.706 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.707 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49407 | ARRB1 | Beta-arrestin-1 | -0.721 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 1 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P47992 | XCL1 | Lymphotactin | -0.706 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.706 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P09769 | FGR | Tyrosine-protein kinase Fgr | 0.796 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.971 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.707 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43250 | GRK6 | G protein-coupled receptor kinase 6 | 0.818 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49407 | ARRB1 | Beta-arrestin-1 | -0.721 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | 0.706 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q8WYR1 | PIK3R5 | Phosphoinositide 3-kinase regulatory subunit 5 | 0.752 |
| | Naltrexone | hsa04064 | NF-kappa B signaling pathway | 4.92E-02 | 6 | P10415, P51617, Q13546, Q9UDY8, Q13077, P24522 | BCL2, IRAK1, RIPK1, MALT1, TRAF1, GADD45A | More | | | Naltrexone | hsa04070 | Phosphatidylinositol signaling system | 4.07E-02 | 4 | P0DP23, Q14643, O14732, P17252 | CALM1, ITPR1, IMPA2, PRKCA | More | | | Naltrexone | hsa04071 | Sphingolipid signaling pathway | 1.82E-04 | 9 | P17252, Q9H228, P01375, Q13362, Q16537, Q9BX95, P04637, P10415, Q9UQC2 | PRKCA, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2, GAB2 | More | | | Naltrexone | hsa04110 | Cell cycle | 1.29E-02 | 4 | P30260, P04637, P49918, P42773 | CDC27, TP53, CDKN1C, CDKN2C | More | | | Naltrexone | hsa04145 | Phagosome | 1.86E-02 | 5 | P63261, Q15080, Q13509, P68371, P27824 | ACTG1, NCF4, TUBB3, TUBB2C, CANX | More | | | Naltrexone | hsa04151 | PI3K-Akt signaling pathway | 6.72E-03 | 15 | P42338, P43657, P04637, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, Q96BR1, P30281, P56279 | PIK3CB, P2RY5, TP53, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, SGK3, CCND3, TCL1A | More | | | Naltrexone | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | | | Naltrexone | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | | | Naltrexone | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.44E-02 | 5 | Q16537, P0DP23, P17252, P10415, P20020 | PPP2R5E, CALM1, PRKCA, BCL2, ATP2B1 | More | | | Naltrexone | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | | Naltrexone | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | | Naltrexone | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | | Naltrexone | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | | Naltrexone | hsa04390 | Hippo signaling pathway | 1.47E-02 | 5 | P63261, Q13485, Q9UJU2, O43623, Q13489 | ACTG1, SMAD4, LEF1, SNAI2, BIRC3 | More | | | Naltrexone | hsa04510 | Focal adhesion | 3.21E-02 | 6 | Q15942, P17252, Q13489, P10415, P49767, P63261 | ZYX, PRKCA, BIRC3, BCL2, VEGFC, ACTG1 | More | | | Naltrexone | hsa04520 | Adherens junction | 3.36E-02 | 4 | Q13485, Q9UJU2, O43623, P63261 | SMAD4, LEF1, SNAI2, ACTG1 | More | | | Naltrexone | hsa04540 | Gap junction | 4.76E-02 | 3 | P17252, Q13509, P68371 | PRKCA, TUBB3, TUBB2C | More | | | Naltrexone | hsa04612 | Antigen processing and presentation | 1.51E-02 | 7 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A | More | | | Naltrexone | hsa04613 | Neutrophil extracellular trap formation | 2.98E-04 | 14 | P17252, P11215, O60603, P08246, Q13547, Q92769, Q6FI13, P58876, P33778, Q16778, O60814, P14598, Q15080, P21462 | PRKCA, ITGAM, TLR2, ELA2, HDAC1, HDAC2, H2AC18; H2AC19, H2BC5, H2BC3, HIST2H2BE, H2BC12, NCF1, NCF4, FPR1 | More | | | Naltrexone | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | | Naltrexone | hsa04650 | Natural killer cell mediated cytotoxicity | 7.01E-05 | 10 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| | Naltrexone | hsa04657 | IL-17 signaling pathway | 3.31E-02 | 3 | P49841, P14780, P01375 | GSK3B, MMP9, TNF | More | | | Naltrexone | hsa04659 | Th17 cell differentiation | 1.70E-02 | 7 | P19174, P14784, P14778, P84022, Q13485, P08238, P07766 | PLCG1, IL2RB, IL1R1, SMAD3, SMAD4, HSP90AB1, CD3E | More | | | Naltrexone | hsa04660 | T cell receptor signaling pathway | 1.49E-03 | 10 | P01375, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| | Naltrexone | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | | Naltrexone | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | | Naltrexone | hsa04666 | Fc gamma R-mediated phagocytosis | 2.22E-02 | 4 | P49006, P06396, P14598, P17252 | MARCKSL1, GSN, NCF1, PRKCA | More | | | Naltrexone | hsa04720 | Long-term potentiation | 3.70E-04 | 5 | P17252, Q16566, P0DP23, O15399, Q14643 | PRKCA, CAMK4, CALM1, GRIN2D, ITPR1 | More | | | Naltrexone | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | | Naltrexone | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | | Naltrexone | hsa04912 | GnRH signaling pathway | 4.42E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | | Naltrexone | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | | Naltrexone | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | | Naltrexone | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | | Naltrexone | hsa04925 | Aldosterone synthesis and secretion | 2.90E-04 | 6 | Q14643, P0DP23, P17252, Q16566, P20020, P23634 | ITPR1, CALM1, PRKCA, CAMK4, ATP2B1, ATP2B4 | More | | | Naltrexone | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | | Naltrexone | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.93E-03 | 7 | P84022, Q13485, P10415, P42338, P49767, P17252, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PRKCA, PLCG1 | More | | | Naltrexone | hsa04966 | Collecting duct acid secretion | 3.15E-02 | 2 | P02730, Q9Y666 | SLC4A1, SLC12A7 | More | | | Naltrexone | hsa04970 | Salivary secretion | 8.71E-04 | 5 | Q14643, P20020, P23634, P17252, P0DP23 | ITPR1, ATP2B1, ATP2B4, PRKCA, CALM1 | More | | | Naltrexone | hsa04971 | Gastric acid secretion | 4.76E-02 | 3 | P17252, P63261, P0DP23 | PRKCA, ACTG1, CALM1 | More | | | Naltrexone | hsa04972 | Pancreatic secretion | 1.00E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | | Naltrexone | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | | | Naltrexone | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | | Naltrexone | hsa05014 | Amyotrophic lateral sclerosis | 4.31E-02 | 7 | O15399, P10415, Q13509, P68371, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, TUBB3, TUBB2C, GLE1, ACTG1, NXF2; NXF2B | More | | | Naltrexone | hsa05031 | Amphetamine addiction | 1.49E-02 | 4 | O15399, P0DP23, Q16566, P17252 | GRIN2D, CALM1, CAMK4, PRKCA | More | | | Naltrexone | hsa05034 | Alcoholism | 2.10E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | | | Naltrexone | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.11E-02 | 4 | Q16539, P25024, P25025, P07948 | MAPK14, CXCR1, CXCR2, LYN | More | | | Naltrexone | hsa05132 | Salmonella infection | 2.12E-04 | 13 | P51617, Q9UJU2, P63261, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371 | IRAK1, LEF1, ACTG1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C | More | | | Naltrexone | hsa05133 | Pertussis | 2.52E-02 | 3 | P0DP23, P23528, P09871 | CALM1, CFL1, C1S | More | | | Naltrexone | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | | Naltrexone | hsa05140 | Leishmaniasis | 1.56E-02 | 5 | P14598, O60603, P49006, P51617, Q15080 | NCF1, TLR2, MARCKSL1, IRAK1, NCF4 | More | | | Naltrexone | hsa05144 | Malaria | 1.64E-03 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | | Naltrexone | hsa05163 | Human cytomegalovirus infection | 1.72E-02 | 8 | P01375, P63218, P50151, P49841, P14778, P25025, Q16539, O00463 | TNF, GNG5, GNG10, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | | | Naltrexone | hsa05168 | Herpes simplex virus 1 infection | 1.94E-02 | 9 | Q9UKJ0, P01568, Q9GZY0, Q01130, Q13489, Q13398, Q03923, Q9UDV6, P10415 | PILRB, IFNA21, NXF2; NXF2B, SFRS2, BIRC3, ZNF211, ZNF85, ZNF212, BCL2 | More | | | Naltrexone | hsa05169 | Epstein-Barr virus infection | 2.54E-02 | 8 | Q92769, P04637, Q13546, P10415, P24522, O60603, P51617, P09693 | HDAC2, TP53, RIPK1, BCL2, GADD45A, TLR2, IRAK1, CD3G | More | | | Naltrexone | hsa05170 | Human immunodeficiency virus 1 infection | 6.54E-03 | 9 | P0DP23, P17252, Q13546, Q14643, P51617, O60603, P09693, P10415, Q9Y6Q5 | CALM1, PRKCA, RIPK1, ITPR1, IRAK1, TLR2, CD3G, BCL2, AP1M2 | More | | | Naltrexone | hsa05200 | Pathways in cancer | 5.18E-04 | 26 | Q13751, P42338, P08238, P19174, Q9UJU2, P17252, P43246, P84022, Q13485, Q13547, P14923, P30281, P10415, Q13489, P49767, P43657, P25116, P63218, P50151, Q14344, Q7LDG7, P78417, O75293, P0DP23, P01568, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, LEF1, PRKCA, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, BCL2, BIRC3, VEGFC, P2RY5, F2R, GNG5, GNG10, GNA13, RASGRP2, GSTO1, GADD45B, CALM1, IFNA21, IL2RB | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P46091 | GPR1 | Chemerin-like receptor 2 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.736 | | P46091 | GPR1 | Chemerin-like receptor 2 | P17252 | PRKCA | Protein kinase C alpha type | 0.741 | | P46091 | GPR1 | Chemerin-like receptor 2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.838 | | P46091 | GPR1 | Chemerin-like receptor 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.809 | | P46091 | GPR1 | Chemerin-like receptor 2 | P14923 | JUP | Junction plakoglobin | 0.883 | | P46091 | GPR1 | Chemerin-like receptor 2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.808 | | P46091 | GPR1 | Chemerin-like receptor 2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.759 | | P46091 | GPR1 | Chemerin-like receptor 2 | P49767 | VEGFC | Vascular endothelial growth factor C | 0.718 | | P46091 | GPR1 | Chemerin-like receptor 2 | P25116 | F2R | Proteinase-activated receptor 1 | 0.76 | | P46091 | GPR1 | Chemerin-like receptor 2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | 0.738 | | P46091 | GPR1 | Chemerin-like receptor 2 | P0DP23 | CALM1 | Calmodulin-1 | -0.846 | | P46091 | GPR1 | Chemerin-like receptor 2 | P01568 | IFNA21 | Interferon alpha-21 | 0.724 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | | P46091 | GPR1 | Chemerin-like receptor 2 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.736 | | P46091 | GPR1 | Chemerin-like receptor 2 | P17252 | PRKCA | Protein kinase C alpha type | 0.741 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | | P46091 | GPR1 | Chemerin-like receptor 2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.838 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | | P46091 | GPR1 | Chemerin-like receptor 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.809 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | | P46091 | GPR1 | Chemerin-like receptor 2 | P14923 | JUP | Junction plakoglobin | 0.883 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | | P46091 | GPR1 | Chemerin-like receptor 2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.808 | | P46091 | GPR1 | Chemerin-like receptor 2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.759 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | | P46091 | GPR1 | Chemerin-like receptor 2 | P49767 | VEGFC | Vascular endothelial growth factor C | 0.718 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | | P46091 | GPR1 | Chemerin-like receptor 2 | P25116 | F2R | Proteinase-activated receptor 1 | 0.76 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | | P46091 | GPR1 | Chemerin-like receptor 2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | 0.738 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | | P46091 | GPR1 | Chemerin-like receptor 2 | P0DP23 | CALM1 | Calmodulin-1 | -0.846 | | P46091 | GPR1 | Chemerin-like receptor 2 | P01568 | IFNA21 | Interferon alpha-21 | 0.724 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 |
| | Naltrexone | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | | | Naltrexone | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | | | Naltrexone | hsa05212 | Pancreatic cancer | 9.39E-03 | 5 | P42338, P37173, P84022, Q13485, O75293 | PIK3CB, TGFBR2, SMAD3, SMAD4, GADD45B | More | | | Naltrexone | hsa05214 | Glioma | 8.71E-04 | 5 | P0DP23, Q16566, P17252, P04637, P24522 | CALM1, CAMK4, PRKCA, TP53, GADD45A | More | | | Naltrexone | hsa05216 | Thyroid cancer | 1.85E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | | Naltrexone | hsa05217 | Basal cell carcinoma | 4.42E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | | Naltrexone | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | | Naltrexone | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | | | Naltrexone | hsa05418 | Fluid shear stress and atherosclerosis | 2.49E-03 | 11 | Q16539, P78417, P10599, P14780, P01375, P63261, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, GSTO1, TXN, MMP9, TNF, ACTG1, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | |
|
